Assessment of β-Adrenoceptor down Regulation in Man

  • A. J. J. Wood

Abstract

A hormone, neurotransmitter or drug produces its effect by combining with a receptor site and initiating a series of changes which culminate in a measurable effect. Although it is well known that increasing the concentration of an agonist which stimulates a receptor will result in an increase in pharmacological effect it has only recently been recognized that changes in receptor function can also alter the magnitude of a pharmacological response. In addition, many drugs, hormones and neurotransmitters have been shown to regulate their own response through alteration in the function of the receptors to which they bind. Thus the magnitude of a response in any individual is dependent on both the concentration of agonist present and available for binding to the receptor site and the number of receptor sites on the effector cell. An increase in receptor number will produce an increase in the response to a given concentration of agonist, that is an increase in sensitivity, and may also produce an increase in the maximal response. Recently, the development of radiolabelled agonists and antagonists which have a very high specific activity has allowed the direct identification of receptors and studies of their function and control to be performed (Lefkowitz, Roth, Pricer & Pastan, 1970; Freychet, Roth & Neville, 1971; Conolly & Greenacre, 1977; Lefkowitz, Mukherjee, Coverstone & Caron, 1974; Aurback, Fedak, Woodjard, Palmer, Hauser & Troxler, 1974; Lefkowitz & Williams, 1977; Williams, Snyderman & Lefkowitz, 1976; Galant, Duriseti, Underwood & Insel, 1978; Newman, Williams, Bishopric & Lefkowitz, 1978).

Keywords

Noradrenaline Adrenaline Catecholamine Propranolol Tate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aurback, G. C., Fedak, S. A., Woodard, C. J., Palmer, J. S., Hauser, D. & Troxler, T. (1974). Beta-adrenergic receptor: stereospecific interaction of iodinated beta-blocking agent with high affinity site. Science, 186, 1223–1224.CrossRefGoogle Scholar
  2. Conolly, M. E. & Greenacre, J. K. (1976). The lymphocyte β-adrenoceptor in normal subjects and patients with bronchial asthma. J. clin. Invest., 58, 1307–1316.PubMedCentralCrossRefPubMedGoogle Scholar
  3. Conolly, M. E. & Greenacre, J. K. (1977). The β-adrenoceptor of the human lymphocyte and human lung parenchyma. Brit. J. Pharmac., 59, 17–23.CrossRefGoogle Scholar
  4. Fraser, J., Nadeau, J. H., Robertson, D. & Wood, A. J. J. (1980a). Down regulation of human leukocyte beta-receptors by physiological levels of catecholamines. Clin. Res., 28, 541A.Google Scholar
  5. Fraser, J., Nadeau, J. H., Robertson, D. & Wood, A. J. J. (1980b). Leukocyte beta-receptor density (Bmax) correlates with cardiac sensitivity to isoproterenol in man. Clin. Res., 28, 475A.Google Scholar
  6. Fraser, J. P. & Wood, A. J. J. (1979). Alterations in beta-receptor density following prolonged propranolol treatment. Circulation, 60, 274.Google Scholar
  7. Freychet, P., Roth, J. & Neville, D. M., Jr. (1971). Monoiodoinsulin: demonstration of its biological activity and binding to fat cells and liver membranes. Biochem. Biophys. Res. Commun., 43, 400–408.CrossRefPubMedGoogle Scholar
  8. Galant, S. P., Duriseti, L., Underwood, S. & Insel, P. A., (1978). Decreased beta-adrenergic receptors on polymorphonuclear leukocytes after adrenergic therapy. New Eng. J. Med., 299, 933–936.CrossRefPubMedGoogle Scholar
  9. Galant, S. P., Underwood, S., Duriseti, L. & Indel, P. A. (1978). Characterization of high affinity beta2-adrenergic receptor binding of (-) 3H dihydroalprenolol to human polymorphonuclear cell particulates. J. lab. clin. Med., 92, 613–618.PubMedGoogle Scholar
  10. Lefkowitz, R. J., Mukherjee, C., Coverstone, M. & Caron, M. G. (1974). Stereospecific 3H (-)-alprenolol binding sites, beta-adrenergic receptor and adenylate cyclase. Biochem. Biophys. Res. Commun., 60, 703–709.CrossRefPubMedGoogle Scholar
  11. Lefkowitz, R. J. & Williams, L. T. (1977). Catecholamine binding to the beta-adrenergic receptor. Proc. Nat. Acad. Sci. USA, 74, 515–519.PubMedCentralCrossRefPubMedGoogle Scholar
  12. Mickey, J., Tate, R. & Lefkowitz, J. (1975). Subsensitivity of adenylate cyclase and decreased beta-adrenergic receptor binding after chronic exposure to (-)isoproterenol in vitro. J. biol. Chem., 250, 5727–5729.PubMedGoogle Scholar
  13. Mukherjee, C., Caron, M. G. & Lefkowitz, R. J. (1976). Regulation of adenylate cyclase coupled beta-adrenergic receptors by beta-adrenergic catecholamines. Endocrinology, 99, 347–357.CrossRefPubMedGoogle Scholar
  14. Nadeau, J. H., Fraser, J., Robertson, D. & Wood, A. J. J. (1980). Increased sodium intake increases sensitivity to catecholamines through alteration in receptor density. Clin. Res., 28, 240A.Google Scholar
  15. Newman, K. D., Williams, L. T., Bishopric, N. H. & Lefkowitz, R. J. (1978). Identification of α-adrenergic receptors in human platelets by [3H]-dihydroergocryptine binding. J. clin. Invest, 61, 395–402.PubMedCentralCrossRefPubMedGoogle Scholar
  16. Schocken, D. D. & Roth, G. S. (1977). Reduced β-adrenergic-reeeptor concentrations in ageing man. Nature, 267, 856–859.CrossRefPubMedGoogle Scholar
  17. Vestal, R. E., Wood, A. J. J. & Shand, D. G. (1979). Reduced beta-adrenoceptor sensitivity in the elderly. Clin. Pharmac. Ther., 26, 181–186.Google Scholar
  18. Williams, L. T., Snyderman, R. & Lefkowitz, R. J. (1976). Identification of β-adrenergic receptors in human leukocytes by (-) [3H]-alprenolol binding. J. clin. Invest., 56, 149–155.CrossRefGoogle Scholar
  19. Wood, A. J. J., Nadeau, J. H., Robertson, D. & Fraser, J. (1979). Human leukocyte beta-receptors are normally down regulated by circulating catecholamines. Clin. Res., 27, 776A.Google Scholar

Copyright information

© The contributors 1980

Authors and Affiliations

  • A. J. J. Wood
    • 1
  1. 1.Vanderbilt University Medical SchoolNashvilleUSA

Personalised recommendations